Maravai LifeSciences Holdings Inc. Class A Common Stock vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $201.83 (market cap $37.46B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 38.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| MRVI | TTWO | |
|---|---|---|
Market Cap | $972.90M | $37.46B |
Volume | 4,325,710 | 5,201,670 |
Sector | Health | Technology |
52-Week High | $9.00 | $262.29 |
52-Week Low | $2.83 | $189.69 |
Typical Hold Time | 0 Days | 111 Days |
Enterprise Value | $1.08B | $38.57B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Take-Two Interactive (TTWO) trades at $201.23, down 3.63% today amid mixed technical signals and volatile earnings performance. The stock shows strong analyst support with 79% buy ratings and a $292.30 consensus price target, representing 45% upside potential. Recent quarterly results have been inconsistent with two beats and one miss, while the company maintains anticipation for Grand Theft Auto VI's November 2026 launch. Fundamentals reveal significant losses with a -79.51% net margin in 2025, though revenue growth continues and cash position remains strong at $1.47 billion.
The investment case hinges on GTA VI's successful execution, with current valuation reflecting high expectations. While analyst optimism remains strong, investors face risks from execution missteps, competitive pressures, and the stock's premium valuation multiples. The substantial negative earnings and cash flow volatility require careful monitoring, though institutional ownership trends show continued confidence in the long-term gaming franchise strategy.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →